How it works
Semaglutide is a long-acting copy of glucagon-like peptide-1 (GLP-1). GLP-1 is a hormone your gut makes after you eat. Semaglutide acts on GLP-1 receptors in three places. In the pancreas, it helps release insulin when your blood sugar is high. In the gut, it slows how fast food leaves your stomach. In the parts of the brain that control hunger, it turns down hunger and 'food noise'.
The evidence
The STEP 1 trial (2021, NEJM) studied adults without diabetes on weekly brand-name semaglutide (Wegovy) 2.4 mg. After 68 weeks, they lost ~14.9% of their body weight on average. People on placebo lost ~2.4%. The SELECT trial (2023) studied people with overweight or obesity who already had heart disease. Wegovy cut major heart events, like heart attack and stroke, by 20%. These trials studied the FDA-approved brand-name products that contain this molecule (Wegovy, Ozempic). The results apply to those products only.
Typical dosing
The dose goes up slowly. This is called titration. You start with a 0.25 mg shot under the skin once a week for 4 weeks. Then the dose steps up every 4 weeks (0.5 → 1.0 → 1.7 → 2.4 mg), as long as your body handles it. The maintenance dose is usually between 1.0 mg and 2.4 mg a week.
Side effects
Common
- Nausea
- Constipation
- Diarrhea
- Tiredness (early on, while the dose goes up)
- Less appetite
Less common
- Acid reflux
- Reactions where you inject
- Gallbladder discomfort
Rare
- Pancreatitis (swelling of the pancreas)
- Sudden kidney injury (linked to dehydration)
Drug interactions
- Insulin and sulfonylureas: higher risk of low blood sugar. Their doses may need to be lowered
- Pills that need very exact dosing (a narrow therapeutic window): absorbed more slowly, because your stomach empties more slowly
- GLP-1 / GIP medicines like tirzepatide: never take them together
Frequently asked
Which products contain semaglutide?
How long until results?
Can I stop and restart?
References
- STEP 1 (brand-name semaglutide, Wegovy) — Wilding et al., NEJM 2021 (n=1,961): −14.9% mean body weight at week 68 vs −2.4% placebo
- SELECT (brand-name semaglutide, Wegovy) — Lincoff et al., NEJM 2023 (n=17,604): 20% relative reduction in major adverse cardiovascular events
- STEP 4 (brand-name semaglutide, Wegovy) — Rubino et al., JAMA 2021: weight regain after discontinuation vs continued treatment

